Who Paid My Doc
Casgevy
Biological Sickle Cell Disease/Beta Thalessemia
NDC 51167-290-09
General payments
$172,900
Research payments
$0
Through program year 2025, $172,900 in general payments and $0 in research payments were reported against Casgevy (Sickle Cell Disease/Beta Thalessemia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $122,065 | 163 |
| 2024 | General | $50,835 | 140 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 25 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 27 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
303 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.